The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report

Abstract

This report summarizes the results of the 3rd Joint ENCCA-WP7, EuroSarc, EEC, PROVABES, and EURAMOS European Bone Sarcoma Network Meeting, which was held at the Children’s Cancer Research Institute in Vienna, Austria on September 24–25, 2015. The joint bone sarcoma network meetings bring together European bone sarcoma researchers to present and discuss current knowledge on bone sarcoma biology, genetics, immunology, as well as results from preclinical investigations and clinical trials, to generate novel hypotheses for collaborative biological and clinical investigations. The ultimate goal is to further improve therapy and outcome in patients with bone sarcomas.

A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy

“…4,6,35 Other efforts to improve patient outcomes have been largely unsuccessful. 7–9,38 It remains to be seen whether novel therapeutic approaches such as immunotherapy will be beneficial in this population. 38 …”

“…7–9,38 It remains to be seen whether novel therapeutic approaches such as immunotherapy will be beneficial in this population. 38 …”

“…4,6,35 Other efforts to improve patient outcomes have been largely unsuccessful. [7][8][9]38 It remains to be seen whether novel therapeutic approaches such as immunotherapy will be beneficial in this population. 38 Consistent with prior reports, we found no significant correlation between 3D anatomic measurements of primary tumor on MRI and histologic response.…”

“…[7][8][9]38 It remains to be seen whether novel therapeutic approaches such as immunotherapy will be beneficial in this population. 38 Consistent with prior reports, we found no significant correlation between 3D anatomic measurements of primary tumor on MRI and histologic response. [39][40][41] This is most likely because the extent of MR signal abnormality in the affected bone typically represents a combination of viable tumor, partially treated tumor, necrosis and bland edema.…”

CORR Insights®: What Factors are Associated With Quality Of Life, Pain Interference, Anxiety, and Depression in Patients With Metastatic Bone Disease?

“…The ways in which physicians communicate with their patients and patients' families have dramatically changed our specialty in the last few years and may eventually influence the surgery-related QOL parameters in patients with bone metastases [4]. Patients are more technically savvy and are more inclined to research their treatment options online.…”